MENU

Multi-diagnostic approaches for patient selection in immuno-oncology

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • VP Scientific Affairs, ICON Laboratory Services
    Biography

      Cindy Spittle is the Vice President of Scientific Affairs within the ICON Laboratory Services group. Dr. Spittle has over 30 years of experience in translational and clinical oncology biomarker research, diagnostic assay development and biomarker strategy for clinical drug development. She provides strategic scientific leadership related to the evaluation and implementation of new technologies and laboratory testing services.


    Abstract

    The development of different classes of immunotherapies that target cancer cells continues to be a rapidly growing area of research. The development of diagnostic tests which can predict patient response to these therapies are crucial to the clinical success of an immunotherapy candidate. Checkpoint inhibitors are one class of immunotherapy that release the breaks on immune cells, enabling them to attack cancer cells. Several checkpoint inhibitors that target the PD-1/PD-L1 axis have been approved for a variety of tumor indications. In some tumor types, the efficacy of these agents has been linked to PD-L1 expression levels, leading to the approval of several PD-L1 IHC assays as companion diagnostics. Advances in clinical research and our understanding of the tumor microenvironment underscore the importance of new markers to assess immune infiltration and abnormal activity in cellular pathways, including DNA damage repair and DNA replication. Multiple biomarker assays and methodologies, beyond PD-L1 expression, are being explored for use in selecting patients for checkpoint inhibitor studies and will be reviewed in this presentation. In addition, biomarkers that could aid in patient selection for other types of immunotherapies will be discussed.

    Learning Objectives:

    1. Define the different classes of immunotherapy being developed for cancer treatment

    2. Identify the utility and limitations of current biomarkers for the selection of patients for checkpoint inhibitor therapy

    3. Compare/contrast methods and assays being used for biomarker analysis


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 18, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 18, 2021 Time: 8:00am (PST) The global pandemic has caused an increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide qu...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    Loading Comments...
    Show Resources
    Attendees
    • See more